Zeinab Mohseni Afshar, A. Babazadeh, A. Janbakhsh, M. Afsharian, S. Ebrahimpour
{"title":"COVID-19疫苗:挑战和解决方案","authors":"Zeinab Mohseni Afshar, A. Babazadeh, A. Janbakhsh, M. Afsharian, S. Ebrahimpour","doi":"10.23736/s2784-8477.21.01921-0","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.","PeriodicalId":29817,"journal":{"name":"Minerva Respiratory Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"COVID-19 vaccines: challenges and solutions\",\"authors\":\"Zeinab Mohseni Afshar, A. Babazadeh, A. Janbakhsh, M. Afsharian, S. Ebrahimpour\",\"doi\":\"10.23736/s2784-8477.21.01921-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.\",\"PeriodicalId\":29817,\"journal\":{\"name\":\"Minerva Respiratory Medicine\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva Respiratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/s2784-8477.21.01921-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/s2784-8477.21.01921-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
